Bill Burkoth

Bill Burkoth

Keine laufenden Positionen mehr

Health Technology
Finance

Profil

Bill Burkoth is managing partner at SVB Capital, responsible for the life science and healthcare practice, bringing more than 20 years of life science venture capital (VC) investing and startup experience to the practice.
Before joining SVB Capital, Bill was an executive director in worldwide business development and a senior partner and founding member of Pfizer Ventures, the venture capital arm of Pfizer Inc. During his 17-year tenure with Pfizer Ventures, Bill sourced and led dozens of venture investments in life science companies across biotechnology, medical devices and tools and diagnostics.
Bill played an instrumental role in numerous successful VC investments, including 4D Molecular Therapeutics (Nasdaq: FDMT), Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), HandyLab (acquired by Becton Dickinson), NeuMoDx (acquired by QIAGEN) and Novocure (Nasdaq: NVCR).
Additionally, he managed international investment partnerships in several overseas markets, including China, Brazil and Africa.

Ehemalige bekannte Positionen von Bill Burkoth

UnternehmenPositionEnde
Private Equity Investor 01.10.2023
Direktor/Vorstandsmitglied -
Sehen Sie sich die Erfahrung von Bill Burkoth im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Bill Burkoth im Detail an

Beziehungen

14

Beziehungen ersten Grades

2

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen2

Health Technology

Finance

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Bill Burkoth